First-in-Human trial tests engineered immune cells against tough prostate cancer
NCT ID NCT05022849
Summary
This is an early-stage study to find a safe dose of a new experimental treatment called JNJ-75229414 for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment involves collecting a patient's own immune cells (T cells), genetically modifying them in a lab to target a protein called KLK2 found on prostate cancer cells, and then infusing them back into the patient. The main goals are to check the safety of different dose levels and see how the body handles the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
University Of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.